ANIX - Anixa Biosciences Inc

QQQ $ 634.11 $ 0.00 (0 %)

DIA $ 475.76 $ 0.00 (0 %)

SPY $ 685.13 $ 0.00 (0 %)

TLT $ 90.32 $ 0.00 (0 %)

GLD $ 368.56 $ 0.00 (0 %)

Previous Close

$ 4.06

Open

$ 4.16

Bid

$ 4.01 x 24

Ask

$ 4.17 x 100

Day's Range

-- - --

52 Week Range

$ 2.07 - $ 4.98

Volume

125,822

Average Volume

Market Cap

133.64M

Beta (5Y Monthly)

$ 0.80

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	09-10-2025	07-31-2025	10-Q
2	05-28-2025	04-30-2025	10-Q
3	03-11-2025	01-31-2025	10-Q
4	01-10-2025	10-31-2024	10-K
5	09-06-2024	07-31-2024	10-Q
6	06-04-2024	04-30-2024	10-Q
7	03-12-2024	01-31-2024	10-Q
8	01-16-2024	10-31-2023	10-K
9	09-06-2023	07-31-2023	10-Q
10	06-14-2023	04-30-2023	10-Q
11	03-17-2023	01-31-2023	10-Q
12	01-04-2023	10-31-2022	10-K
13	09-09-2022	07-31-2022	10-Q
14	06-10-2022	04-30-2022	10-Q
15	03-11-2022	01-31-2022	10-Q
16	01-04-2022	10-31-2021	10-K
17	09-01-2021	07-31-2021	10-Q
18	06-10-2021	04-30-2021	10-Q
19	03-11-2021	01-31-2021	10-Q
20	01-07-2021	10-31-2020	10-K
21	09-08-2020	07-31-2020	10-Q
22	06-09-2020	04-30-2020	10-Q
23	03-09-2020	01-31-2020	10-Q
24	01-09-2020	10-31-2019	10-K
25	09-06-2019	07-31-2019	10-Q
26	06-12-2019	04-30-2019	10-Q
27	03-13-2019	01-31-2019	10-Q
28	01-11-2019	10-31-2018	10-K
29	09-07-2018	07-31-2018	10-Q
30	06-11-2018	04-30-2018	10-Q
31	03-09-2018	12-01-2017	10-Q
32	01-09-2018	10-31-2017	10-K
33	09-08-2017	07-31-2017	10-Q
34	05-26-2017	04-30-2017	10-Q
35	03-16-2017	01-31-2017	10-Q
36	12-07-2016	10-31-2016	10-K
37	08-19-2016	07-31-2016	10-Q
38	05-20-2016	04-30-2016	10-Q
39	02-19-2016	01-31-2016	10-Q
40	12-23-2015	10-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Anixa Announces That The Chinese National ...
10/20/2025 12:27:20

Expands global intellectual property coverage in markets with high breast cancer incidence New patent will provide IP protecti...

D. Boral Capital Maintains Buy on Anixa Bi...
10/07/2025 14:52:37

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

Anixa Biosciences Completes The Final Pati...
10/07/2025 12:46:30

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatm...

D. Boral Capital Maintains Buy on Anixa Bi...
09/22/2025 14:07:33

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

Anixa To Present Phase 1 Breast Cancer Vac...
09/22/2025 12:09:08

Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and PreventionComprehensive Re...

HC Wainwright & Co. Reiterates Buy on Anix...
09/11/2025 10:19:44

HC Wainwright & Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $7 price target.

Anixa Biosciences Files For Mixed Shelf Of...
09/11/2025 00:06:17

- SEC Filing

Anixa Biosciences Q3 EPS $(0.07) Beats $(0...
09/10/2025 20:36:59

Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0...

D. Boral Capital Maintains Buy on Anixa Bi...
09/09/2025 12:38:09

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

Anixa Biosciences Completes Dosing Of Four...
09/08/2025 12:09:36

Continue to observe a positive safety profile—no dose limiting toxicities, cytokinerelease syndrome or immune effector cell-ass...

Anixa Biosciences Receives CNIPA Notice Of...
08/20/2025 12:42:54

Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer VaccineExpands global intellectual property ...

D. Boral Capital Maintains Buy on Anixa Bi...
08/19/2025 11:20:49

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

Anixa Biosciences Announces Second Patient...
08/18/2025 13:02:43

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatm...

Anixa Biosciences Secures New Patent Exten...
08/12/2025 12:08:21

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045SAN JOSE, Calif., Aug. 12, 2025 /PRNews...

Annexon Announces That The European Medici...
08/07/2025 20:35:02

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, a...

D. Boral Capital Maintains Buy on Anixa Bi...
08/05/2025 11:46:44

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

Anixa Biosciences Advances Breast Cancer V...
08/04/2025 12:45:54

Progress Follows Positive Immune Response Observed in Phase 1 StudySAN JOSE, Calif., Aug. 4, 2025 /PRNewswire/ -- Anixa Bioscie...

Anixa Biosciences Issued Notice Of Allowan...
07/30/2025 12:20:23

Anixa Biosciences Announces It Has Been Aw...
07/24/2025 12:03:46

Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine PlatformTechnology Addresses Substantial Unmet Need in Preve...

Anixa Biosciences Announces Issuance Of US...
07/09/2025 12:10:48